Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ibandronic acid
Drug ID BADD_D01117
Description Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805]
Indications and Usage For the treatment and prevention of osteoporosis in postmenopausal women.[L13805,L13808]
Marketing Status approved; investigational
ATC Code M05BA06
DrugBank ID DB00710
KEGG ID D08056
MeSH ID D000077557
PubChem ID 60852
TTD Drug ID D08SJZ
NDC Product Code Not Available
UNII UMD7G2653W
Synonyms Ibandronic Acid | Ibandronate | 1-Hydroxy-3-(methylpentylamino)propylidenebisphosphonate | (1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonate | Ibandronate Sodium Anhydrous | Boniva | Bonviva | Ibandronate Sodium | Ibandronic Acid, Sodium Salt, Monohydrate | RPR 102289A | RPR-102289A | RPR102289A | Bondronat | BM 21.0955 | BM 210955 | BM-21.0955 | BM21.0955 | BM-210955 | BM210955
Chemical Information
Molecular Formula C9H23NO7P2
CAS Registry Number 114084-78-5
SMILES CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.0010.005163%
Uveitis10.02.01.023; 06.04.03.0030.000697%
Vaginal infection21.14.02.002; 11.01.10.002--
Vertigo04.04.01.003; 17.02.12.002--
Visual impairment06.02.10.0130.002312%Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Infusion site erythema23.03.06.016; 12.07.05.009; 08.02.05.0080.001077%Not Available
Joint range of motion decreased15.01.02.0060.001235%
Onychoclasis23.02.05.0050.001077%Not Available
Peripheral swelling08.01.03.053; 02.05.04.0150.010390%Not Available
Acute phase reaction08.01.05.0040.001774%Not Available
Osteopenia15.02.03.003; 14.04.04.0040.001235%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.001235%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.002851%
Eye pruritus06.04.05.0060.000697%Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal stiffness15.03.05.0270.002629%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling12.07.03.018; 08.02.03.0170.017707%Not Available
Infusion site pain12.07.05.002; 08.02.05.0140.002312%Not Available
Infusion site swelling08.02.05.002; 12.07.05.0030.001235%Not Available
Oesophageal discomfort07.01.06.0300.000317%Not Available
Vascular rupture24.03.02.023; 12.01.11.0060.001774%Not Available
Injection site discomfort12.07.03.019; 08.02.03.0180.001615%Not Available
Haemorrhage24.07.01.002--Not Available
Paraesthesia oral17.02.06.008; 07.05.05.0350.000697%Not Available
Angiopathy24.03.02.007--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.0270.001615%
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages